# A Combination of AKR1B10 and CA19-9 Improves the Diagnosis of PDAC

> **NCT04726956** · — · COMPLETED · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 258 (actual)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04726956
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-02-01
- **Target enrollment:** 258 (ACTUAL)
- **Last updated:** 2024-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04726956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04726956, "A Combination of AKR1B10 and CA19-9 Improves the Diagnosis of PDAC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04726956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*